Patents-Review.com
ClassID:

109169 ⎘

C12N2310/32 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure of the sugar

Sub-classes:
Recent Application in this class:
#1
20260125661
2026-05-07

Compositions and Methods for Kallikrein (KLKB1) Gene Editing

 #2
20260098263
2026-04-09

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #3
20260022358
2026-01-22

Compositions and Methods for Kallikrein (KLKB1) Gene Editing

 #4
20250333736
2025-10-30

BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACID

 #5
20250243485
2025-07-31

Targeting Ligands For Therapeutic Compounds

 #6
20250230435
2025-07-17

METHODS OF TREATMENT OF GNAQ AND GNA11 DRIVEN DISEASE

 #7
20250207128
2025-06-26

POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF

 #8
20250197863
2025-06-19

GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY

 #9
20250197828
2025-06-19

Compositions and Methods for Kallikrein (KLKB1) Gene Editing

 #10
20250177433
2025-06-05

COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION

 #11
20250163401
2025-05-22

ENGINEERED RNA LIGASES

 #12
20250146024
2025-05-08

Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription

 #13
20250122537
2025-04-17

Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription

 #14
20250101422
2025-03-27

METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT

 #15
20250066792
2025-02-27

COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION

 #16
20250059539
2025-02-20

SGLT-2 TARGETING OLIGONUCLEOTIDES

 #17
20250051777
2025-02-13

OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION

 #18
20250034572
2025-01-30

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #19
20250032459
2025-01-30

METHOD FOR TREATING NEURODEGENERATIVE DISEASES

 #20
20250011793
2025-01-09

Oligonucleotides for Modulating Synaptogyrin-3 Expression

 #21
20240417756
2024-12-19

Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription

 #22
20240409942
2024-12-12

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #23
20240401059
2024-12-05

COMPOSITIONS AND METHODS FOR MODULATING PNPLA3 EXPRESSION

 #24
20240175023
2024-05-30

GalNAc compositions for improving siRNA bioavailability

 #25
20240175018
2024-05-30

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF

 #26
20240166678
2024-05-23

Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA)

 #27
20240141351
2024-05-02

ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE

 #28
20240117343
2024-04-11

METHODS AND COMPOSITIONS FOR PREPARING NUCLEIC ACID SEQUENCING LIBRARIES

 #29
20240076676
2024-03-07

MODULATORS OF PNPLA3 EXPRESSION

 #30
20240076675
2024-03-07

MODULATORS OF PNPLA3 EXPRESSION

 #31
20240067973
2024-02-29

Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infection

 #32
20240059784
2024-02-22

TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES

 #33
20240026363
2024-01-25

RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

 #34
20240026360
2024-01-25

OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION

 #35
20240018552
2024-01-18

NOVEL CRISPR ENZYMES AND SYSTEMS

 #36
20240018496
2024-01-18

Compositions and Methods for Kallikrein (KLKB1) Gene Editing

 #37
20240002853
2024-01-04

NUCLEIC ACID DUPLEXES

 #38
20230416737
2023-12-28

RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use

 #39
20230399643
2023-12-14

COMPLEMENT COMPONENT C1S INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME

 #40
20230392146
2023-12-07

OLIGONUCLEOTIDES FOR APP MODULATION

 #41
20230357771
2023-11-09

p21 mRNA target areas for silencing

 #42
20230348907
2023-11-02

OLIGONUCLEOTIDES FOR MECP2 MODULATION

 #43
20230340495
2023-10-26

APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS

 #44
20230340485
2023-10-26

ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

 #45
20230340475
2023-10-26

OLIGONUCLEOTIDES FOR MLH1 MODULATION

 #46
20230313201
2023-10-05

APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS

 #47
20230313191
2023-10-05

RNA COMPRISING SECRETOMES AND METHODS OF THEIR USE

 #48
20230295630
2023-09-21

GalNAc compositions for improving siRNA bioavailability

 #49
20230295587
2023-09-21

Compositions and Methods for Kallikrein (KLKB1) Gene Editing

 #50
20230287434
2023-09-14

APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS

 #51
20230287433
2023-09-14

APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONS

 #52
20230287432
2023-09-14

G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #53
20230265437
2023-08-24

RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use

 #54
20230227826
2023-07-20

UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES

 #55
20230220393
2023-07-13

METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT

 #56
20230212614
2023-07-06

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA DIRECTED MODULATION OF TRANSCRIPTION

 #57
20230212578
2023-07-06

COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA

 #58
20230203498
2023-06-29

SINGLE-STRANDED OLIGONUCLEOTIDE

 #59
20230203496
2023-06-29

SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION

 #60
20230183701
2023-06-15

Modified double-stranded RNA agents

 #61
20230183692
2023-06-15

USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION

 #62
20230159924
2023-05-25

PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR

 #63
20230147811
2023-05-11

MODULATORS OF GROWTH HORMONE RECEPTOR

 #64
20230129651
2023-04-27

HAIRPIN STRUCTURE NUCLEIC ACID MOLECULES CAPABLE OF MODULATING TARGET GENE EXPRESSION AND USES THEREOF

 #65
20230110876
2023-04-13

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #66
20230108784
2023-04-06

NOVEL CRISPR ENZYMES AND SYSTEMS

 #67
20230104708
2023-04-06

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

 #68
20230073999
2023-03-09

POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION

 #69
20220389424
2022-12-08

Modified double-stranded RNA agents

 #70
20220364098
2022-11-17

Compositions and methods for modulating PNPLA3 expression

 #71
20220282248
2022-09-08

MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER

 #72
20220267928
2022-08-25

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #73
20220267808
2022-08-25

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #74
20220267807
2022-08-25

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #75
20220259620
2022-08-18

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #76
20220259592
2022-08-18

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

 #77
20220243200
2022-08-04

COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION

 #78
20220177884
2022-06-09

Oligonucleotides for modulating Tau expression

 #79
20220170015
2022-06-02

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #80
20220162602
2022-05-26

POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF

 #81
20220112521
2022-04-14

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #82
20220056448
2022-02-24

Modified double-stranded RNA agents

 #83
20220049276
2022-02-17

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #84
20220042013
2022-02-10

Compositions and their uses directed to huntingtin

 #85
20220025407
2022-01-27

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #86
20220010338
2022-01-13

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #87
20220002727
2022-01-06

MODIFIED DOUBLE-STRANDED RNA AGENTS

 #88
20210403916
2021-12-30

Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

 #89
20210403914
2021-12-30

Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer

 #90
20210388395
2021-12-16

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #91
20210388394
2021-12-16

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #92
20210371866
2021-12-02

Methods and compositions for treatment of cholesteryl ester storage disease

 #93
20210348163
2021-11-11

The Microbiome as a Target of MicroRNAs for the Treatment of Disease

 #94
20210340575
2021-11-04

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #95
20210332391
2021-10-28

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #96
20210332390
2021-10-28

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #97
20210317452
2021-10-14

SERPINA1 iRNA compositions and methods of use thereof

 #98
20210292352
2021-09-23

Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)

 #99
20210284999
2021-09-16

Application of microRNA-210 inhibitor in preparation of drugs for treating inflammatory skin diseases

 #100
20210254066
2021-08-19

Nucleic acid molecules and uses thereof

 #101
20210230639
2021-07-29

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #102
20210222205
2021-07-22

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #103
20210189394
2021-06-24

Targeting ligands for therapeutic compounds

 #104
20210163934
2021-06-03

BBB-crossing lipid ligand of hetero nucleic acid

 #105
20210123054
2021-04-29

Oligonucleotides for modulating Tau expression

 #106
20210115442
2021-04-22

O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES

 #107
20210108231
2021-04-15

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #108
20210108211
2021-04-15

MODULATORS OF GROWTH HORMONE RECEPTOR

 #109
20210087588
2021-03-25

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #110
20210079428
2021-03-18

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #111
20210079401
2021-03-18

Modulators of PNPLA3 expression

 #112
20210062226
2021-03-04

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #113
20210062225
2021-03-04

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #114
20210062224
2021-03-04

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #115
20210062223
2021-03-04

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #116
20210062198
2021-03-04

Interfering RNA molecules

 #117
20210052631
2021-02-25

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

 #118
20210047640
2021-02-18

COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA

 #119
20210040480
2021-02-11

Compounds and methods for the modulation of amyloid-β precursor protein

 #120
20210017522
2021-01-21

COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN

 #121
20210017519
2021-01-21

Modified double-stranded RNA agents

 #122
20210010003
2021-01-14

Combination comprising immunostimulatory oligonucleotides

 #123
20200392498
2020-12-17

POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS

 #124
20200385722
2020-12-10

5′ modified nucleosides and oligomeric compounds prepared therefrom

 #125
20200362370
2020-11-19

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #126
20200362343
2020-11-19

METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT

 #127
20200354749
2020-11-12

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #128
20200354748
2020-11-12

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #129
20200354747
2020-11-12

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #130
20200339985
2020-10-29

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

 #131
20200318116
2020-10-08

Compositions and their uses directed to huntingtin

 #132
20200299734
2020-09-24

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #133
20200299733
2020-09-24

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #134
20200255824
2020-08-13

Methods and compositions for preparing nucleic acid sequencing libraries

 #135
20200239888
2020-07-30

Compositions and methods for modulation of protein aggregation

 #136
20200216805
2020-07-09

GENE EDITING T CELL AND USE THEREOF

 #137
20200208149
2020-07-02

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #138
20200190542
2020-06-18

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #139
20200190515
2020-06-18

Oligonucleotide compositions and methods of use thereof

 #140
20200163941
2020-05-28

Method for treating neurodegenerative diseases

 #141
20200140869
2020-05-07

Modulators of PNPLA3 expression

 #142
20200123546
2020-04-23

ANTISENSE NUCLEIC ACID FOR TREATING AMYOTROPHY

 #143
20200095578
2020-03-26

POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF

 #144
20200080113
2020-03-12

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #145
20200080112
2020-03-12

Crispr enzymes and systems

 #146
20200080085
2020-03-12

Serpina1 iRNA compositions and methods of use thereof

 #147
20200010831
2020-01-09

Oligonucleotides for modulating Tau expression

 #148
20200002703
2020-01-02

Aptamers for personal care applications

 #149
20200002701
2020-01-02

Reduced size self-delivering RNAI compounds

 #150
20190390201
2019-12-26

Interfering RNA molecules

 #151
20190367921
2019-12-05

Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

 #152
20190365716
2019-12-05

Method for treating neurodegenerative diseases

 #153
20190330662
2019-10-31

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #154
20190323012
2019-10-24

TNF-alpha-binding aptamer, and therapeutic use for same

 #155
20190316134
2019-10-17

Combination comprising immunostimulatory oligonucleotides

 #156
20190309292
2019-10-10

Compounds and methods for enhanced cellular uptake

 #157
20190300878
2019-10-03

METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT

 #158
20190284583
2019-09-19

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #159
20190276832
2019-09-12

Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

 #160
20190271008
2019-09-05

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #161
20190264236
2019-08-29

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #162
20190264235
2019-08-29

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #163
20190264234
2019-08-29

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #164
20190264233
2019-08-29

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #165
20190256871
2019-08-22

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #166
20190256870
2019-08-22

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #167
20190256869
2019-08-22

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #168
20190241893
2019-08-08

Modified double-stranded RNA agents

 #169
20190241891
2019-08-08

Modified double-stranded RNA agents

 #170
20190225970
2019-07-25

MODULATORS OF GROWTH HORMONE RECEPTOR

 #171
20190211333
2019-07-11

Targeting Ligands For Therapeutic Compounds

 #172
20190169649
2019-06-06

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #173
20190169648
2019-06-06

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #174
20190169647
2019-06-06

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #175
20190169646
2019-06-06

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #176
20190169645
2019-06-06

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #177
20190169644
2019-06-06

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #178
20190169643
2019-06-06

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #179
20190169642
2019-06-06

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #180
20190169641
2019-06-06

Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #181
20190119683
2019-04-25

Single-stranded oligonucleotide

 #182
20190106715
2019-04-11

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #183
20190106714
2019-04-11

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #184
20190106713
2019-04-11

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #185
20190106712
2019-04-11

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #186
20190106711
2019-04-11

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #187
20190093129
2019-03-28

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #188
20190062790
2019-02-28

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #189
20190062744
2019-02-28

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

 #190
20190024089
2019-01-24

Interfering RNA molecules

 #191
20190010520
2019-01-10

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #192
20190002923
2019-01-03

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #193
20190002922
2019-01-03

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #194
20190002921
2019-01-03

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #195
20180346913
2018-12-06

Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference

 #196
20180346910
2018-12-06

Serpina1 iRNA compositions and methods of use thereof

 #197
20180340178
2018-11-29

Compositions and their uses directed to huntingtin

 #198
20180340177
2018-11-29

siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene

 #199
20180312876
2018-11-01

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #200
20180312875
2018-11-01

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #201
20180312874
2018-11-01

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #202
20180298407
2018-10-18

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #203
20180298406
2018-10-18

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

 #204
20180291381
2018-10-11

Interfering RNA molecules

 #205
20180282764
2018-10-04

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #206
20180273945
2018-09-27

Compositions and their uses directed to huntingtin

 #207
20180273944
2018-09-27

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

 #208
20180273942
2018-09-27

Compounds and methods for modulation of DUX4

 #209
20180263925
2018-09-20

METHODS FOR THE TREATMENT OF ALOPECIA AREATA UTILIZING GENE MODULATION APPROACHES

 #210
20180251767
2018-09-06

Combination comprising immunostimulatory oligonucleotides

 #211
20180237776
2018-08-23

Methods and compositions for modlating apolipoprotein (A) expression

 #212
20180223286
2018-08-09

Interfering RNA molecules

 #213
20180208931
2018-07-26

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #214
20180208929
2018-07-26

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

 #215
20180201931
2018-07-19

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

 #216
20180201928
2018-07-19

Micromirs

 #217
20180195069
2018-07-12

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #218
20180171393
2018-06-21

Monitoring and analysis of nucleic acid hybridization state and amplification using L-DNA

 #219
20180148725
2018-05-31

UNA oligomers and compositions for treating amyloidosis

 #220
20180135051
2018-05-17

Therapeutic oligomers for treating amyloidosis

 #221
20180119152
2018-05-03

Antisense compounds targeting genes associated with cystic fibrosis

 #222
20180080023
2018-03-22

MIRNA MIMETICS AND THEIR USE IN TREATING SENSORY CONDITIONS

 #223
20180051283
2018-02-22

Compositions and methods for modulating Tau expression

 #224
20180010128
2018-01-11

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

 #225
20180010126
2018-01-11

ANTISENSE COMPOUNDS AND USES THEREOF

 #226
20170369875
2017-12-28

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

 #227
20170362596
2017-12-21

Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition

 #228
20170355995
2017-12-14

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

 #229
20170354673
2017-12-14

Oligonucleotide having non-natural nucleotide at 5′-terminal thereof

 #230
20170349895
2017-12-07

NUCLEASE-RESISTANT DNA ANALOGUES

 #231
20170304269
2017-10-26

Method for treating neurodegenerative diseases

 #232
20170275626
2017-09-28

Modified double-stranded RNA agents

 #233
20170275618
2017-09-28

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA

 #234
20170268002
2017-09-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

 #235
20170260221
2017-09-14

Ruthenium-based photolinkers and methods of use

 #236
20170253876
2017-09-07

Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)

 #237
20170253875
2017-09-07

Targeting ligands for therapeutic compounds

 #238
20170233737
2017-08-17

Means and Methods for the Treatment of Nephropathy

 #239
20170191061
2017-07-06

Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA

 #240
20170183659
2017-06-29

Polynucleotide agents targeting complement component C5 and methods of use thereof

 #241
20170166893
2017-06-15

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #242
20170159056
2017-06-08

ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF

 #243
20170145414
2017-05-25

Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN

 #244
20170121710
2017-05-04

Methods and compositions for modulating apolipoprotein (a) expression

 #245
20170114342
2017-04-27

Serpina1 iRNA compositions and methods of use thereof

 #246
20170114341
2017-04-27

POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS

 #247
20170096668
2017-04-06

Compounds and methods for enhanced cellular uptake

 #248
20170073689
2017-03-16

MODULATORS OF GROWTH HORMONE RECEPTOR

 #249
20170051310
2017-02-23

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #250
20170051286
2017-02-23

METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT

 #251
20170037403
2017-02-09

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

 #252
20170037402
2017-02-09

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

 #253
20170029815
2017-02-02

RNAi agents modified at the 4′-C position

 #254
20160369273
2016-12-22

Compositions and their uses directed to huntingtin

 #255
20160348110
2016-12-01

NUCLEIC ACID CHEMICAL MODIFICATIONS

 #256
20160333356
2016-11-17

Oligonucleotide modulators of the toll-like receptor pathway

 #257
20160326526
2016-11-10

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

 #258
20160304877
2016-10-20

COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION

 #259
20160304875
2016-10-20

METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES

 #260
20160281091
2016-09-29

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA

 #261
20160272975
2016-09-22

CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE

 #262
20160244767
2016-08-25

Antisense compounds targeting genes associated with cystic fibrosis

 #263
20160222385
2016-08-04

Compositions and methods related to miRNA modulation of neovascularization or angiogenesis

 #264
20160168568
2016-06-16

Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)

 #265
20160159846
2016-06-09

Methods and compounds useful in conditions related to repeat expansion

 #266
20160152973
2016-06-02

Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference

 #267
20160145606
2016-05-26

Nuclease-resistant DNA analogues

 #268
20160138008
2016-05-19

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #269
20160130609
2016-05-12

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

 #270
20160130587
2016-05-12

Interfering RNA molecules

 #271
20160130578
2016-05-12

Reduced size self-delivering RNAi compounds

 #272
20160108399
2016-04-21

Modulation of HSP47 expression

 #273
20160090598
2016-03-31

Antisense compounds and uses thereof

 #274
20160051573
2016-02-25

Structure and use of 5′ phosphate oligonucleotides

 #275
20160046939
2016-02-18

5′ modified nucleosides and oligomeric compounds prepared therefrom

 #276
20160032286
2016-02-04

Inhibitors of MYH7B and uses thereof

 #277
20160032285
2016-02-04

Compositions and methods for modulating Tau expression

 #278
20160017329
2016-01-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

 #279
20160008389
2016-01-14

Cell-penetrating oligonucleotides

 #280
20150376611
2015-12-31

Oligonucleotide

 #281
20150368647
2015-12-24

Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features

 #282
20150361427
2015-12-17

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

 #283
20150344886
2015-12-03

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

 #284
20150344880
2015-12-03

Compositions and methods related to miRNA modulation of neovascularization or angiogenesis

 #285
20150337318
2015-11-26

RNA TARGETED TO C-MET

 #286
20150337304
2015-11-26

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

 #287
20150322435
2015-11-12

Formulations for treating amyloidosis

 #288
20150307881
2015-10-29

UNA OLIGOMERS HAVING REDUCED OFF-TARGET EFFECTS IN GENE SILENCING

 #289
20150307880
2015-10-29

Transthyretin allele selective UNA oligomers for gene silencing

 #290
20150307877
2015-10-29

Compositions and their uses directed to huntingtin

 #291
20150299701
2015-10-22

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

 #292
20150299699
2015-10-22

MICROMIRs

 #293
20150291957
2015-10-15

METHODS AND COMPOSITIONS TO PRODUCE ss-RNAi ACTIVITY WITH ENHANCED POTENCY

 #294
20150275283
2015-10-01

Modified cytosine polynucleotide oligomers and methods

 #295
20150267195
2015-09-24

Oligomeric compounds comprising bicyclic nucleosides and uses thereof

 #296
20150259685
2015-09-17

Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

 #297
20150232850
2015-08-20

Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)

 #298
20150225725
2015-08-13

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

 #299
20150225724
2015-08-13

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

 #300
20150197746
2015-07-16

Modified RNAi agents